DrugPatentWatch Database Preview
J And J Company Profile
What is the competitive landscape for J AND J, and when can generic versions of J AND J drugs launch?
J AND J has thirty-two approved drugs.
There are eight US patents protecting J AND J drugs.
There are one hundred and three patent family members on J AND J drugs in forty-three countries and sixteen supplementary protection certificates in eight countries.
Summary for J And J
| International Patents: | 103 |
| US Patents: | 8 |
| Tradenames: | 25 |
| Ingredients: | 12 |
| NDAs: | 32 |
Drugs and US Patents for J And J
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| J And J Consumer Inc | IMODIUM | loperamide hydrochloride | CAPSULE;ORAL | 017690-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| J And J Consumer Inc | CHILDREN'S ZYRTEC ALLERGY | cetirizine hydrochloride | SYRUP;ORAL | 022155-002 | Nov 16, 2007 | OTC | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| J And J Consumer Inc | ZYRTEC HIVES RELIEF | cetirizine hydrochloride | TABLET;ORAL | 019835-005 | Nov 16, 2007 | DISCN | Yes | No | ➤ Sign Up | ➤ Sign Up | |||||
| J And J Consumer Inc | IMODIUM A-D | loperamide hydrochloride | SOLUTION;ORAL | 019487-001 | Mar 1, 1988 | OTC | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| J And J Consumer Inc | ZYRTEC ALLERGY | cetirizine hydrochloride | TABLET;ORAL | 019835-003 | Nov 16, 2007 | DISCN | Yes | No | ➤ Sign Up | ➤ Sign Up | |||||
| J And J Consumer Inc | IBUPROFEN | ibuprofen | TABLET;ORAL | 070081-001 | Jun 16, 1986 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for J And J
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| J And J Consumer Inc | TYLENOL | acetaminophen | TABLET, EXTENDED RELEASE;ORAL | 019872-001 | Jun 8, 1994 | 4,820,522 | ➤ Sign Up |
| J And J Consumer Inc | ZYRTEC | cetirizine hydrochloride | SYRUP;ORAL | 020346-001 | Sep 27, 1996 | 4,525,358*PED | ➤ Sign Up |
| J And J Consumer Inc | IMODIUM A-D EZ CHEWS | loperamide hydrochloride | TABLET, CHEWABLE;ORAL | 020448-001 | Jul 24, 1997 | 5,489,436 | ➤ Sign Up |
| J And J Consumer Inc | PEPCID AC | famotidine | TABLET, CHEWABLE;ORAL | 020801-001 | Sep 24, 1998 | 5,075,114*PED | ➤ Sign Up |
| J And J Consumer Inc | IMODIUM | loperamide hydrochloride | CAPSULE;ORAL | 017694-001 | Approved Prior to Jan 1, 1982 | 3,714,159 | ➤ Sign Up |
| J And J Consumer Inc | PEPCID AC | famotidine | TABLET, CHEWABLE;ORAL | 020801-002 | Dec 17, 2007 | 5,075,114*PED | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for J AND J drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Chewable Tablets | 5 mg and 10 mg | ➤ Subscribe | 2005-03-25 |
| ➤ Subscribe | Syrup | 5 mg/5 mL | ➤ Subscribe | 2007-03-19 |
| ➤ Subscribe | Chewable Tablets | 800 mg/ 10 mg/ 165 mg (OTC) | ➤ Subscribe | 2004-11-01 |
International Patents for J And J Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| China | 100490809 | ➤ Sign Up |
| Poland | 337794 | ➤ Sign Up |
| Australia | 723364 | ➤ Sign Up |
| World Intellectual Property Organization (WIPO) | 9814198 | ➤ Sign Up |
| New Zealand | 530289 | ➤ Sign Up |
| Mexico | 9702532 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for J And J Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2008006,C0933372 | Lithuania | ➤ Sign Up | PRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712 |
| 0689 | Netherlands | ➤ Sign Up | PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ATORVASTATINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER ATORVASTATINE CALCIUM TRIHYDRATE; NATIONAL REGISTRATION NO/DATE: RVG114373-114376 20141027; FIRST REGISTRATION: FR 2014091200122 20140912 |
| C/GB03/033 | United Kingdom | ➤ Sign Up | PRODUCT NAME: ROSUVASTATIN OPTIONALLY IN THE FORM OF A NON-TOXIC PHARMACEUTICALLY ACCEPTABLE SALT, PARTICULARLY THE CALCIUM SALT.; REGISTERED: NL 26872 20021106; NL 26873 20021106; NL 26874 20021106; UK PL 17901/0201 20030321; UK PL 17901/0202 20030321; UK PL 17901/0203 20030321 |
| C/GB08/005 | United Kingdom | ➤ Sign Up | SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022. |
| C/GB98/013 | United Kingdom | ➤ Sign Up | PRODUCT NAME: LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE; REGISTERED: UK 00242/0314 19970923 |
| 2014 00050 | Denmark | ➤ Sign Up | PRODUCT NAME: EZETIMIBE AND ATORVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING ATORVASTATIN AS ATORVASTATIN CALCIUM TRIHYDRATE; REG. NO/DATE: DE/H/3895-3898/001-004/DC 20140910 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
